Literature DB >> 15637123

Antisense oligodeoxyribonucleotide as to the growth factor midkine suppresses neointima formation induced by balloon injury.

Kenji Hayashi1, Hiroshi Banno, Kenji Kadomatsu, Yoshifumi Takei, Kimihiro Komori, Takashi Muramatsu.   

Abstract

Restenosis is the major clinical problem of angioplasty. We have previously shown that neointima formation is strikingly suppressed in midkine (MK)-deficient mice. Neointima formation is restored if MK protein is administrated to the deficient mice. MK is a heparin-binding growth factor and implicated in the migration of inflammatory cells and vascular smooth muscle cells. Consistently, the suppression of neointima formation in the deficient mice is accompanied by suppression of recruitment of inflammatory cells into the vascular wall. Here, we evaluated the potential of MK antisense oligodeoxyribonucleotide (ODN) for the prevention of restenosis. We cloned the cDNA of rabbit MK, which showed a strongly conserved sequence in mammals. The balloon injury induced MK expression, with the maximum level occurring 7-14 days after angioplasty, in the rabbit carotid artery. Two antisense ODNs suppressed the production of MK in a rabbit kidney cell line, RK13 cells, one of which was then transfected into the arterial wall by means of lipofection immediately after balloon treatment. The antisense ODN suppressed MK induction in vivo and consequently suppressed neointima formation to 60% of the control level. These results suggest that MK is a candidate molecular target for the therapy for vascular restenosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15637123     DOI: 10.1152/ajpheart.00555.2004

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  7 in total

Review 1.  Delivery of large biopharmaceuticals from cardiovascular stents: a review.

Authors:  Hironobu Takahashi; Didier Letourneur; David W Grainger
Journal:  Biomacromolecules       Date:  2007-10-12       Impact factor: 6.988

2.  Growth factor midkine is involved in the pathogenesis of diabetic nephropathy.

Authors:  Tomoki Kosugi; Yukio Yuzawa; Waichi Sato; Hanayo Kawai; Seiichi Matsuo; Yoshifumi Takei; Takashi Muramatsu; Kenji Kadomatsu
Journal:  Am J Pathol       Date:  2006-01       Impact factor: 4.307

Review 3.  Therapeutic potential of midkine in cardiovascular disease.

Authors:  Kenji Kadomatsu; Péter Bencsik; Anikó Görbe; Csaba Csonka; Kazuma Sakamoto; Satoshi Kishida; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

4.  Midkine inhibitors: application of a simple assay procedure to screening of inhibitory compounds.

Authors:  Takashi Matsui; Keiko Ichihara-Tanaka; Chen Lan; Hisako Muramatsu; Toshiharu Kondou; Chizuru Hirose; Sadatoshi Sakuma; Takashi Muramatsu
Journal:  Int Arch Med       Date:  2010-06-21

Review 5.  Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases.

Authors:  Takashi Muramatsu
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2010       Impact factor: 3.493

Review 6.  Midkine: a promising molecule for drug development to treat diseases of the central nervous system.

Authors:  Takashi Muramatsu
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

Review 7.  Midkine-A novel player in cardiovascular diseases.

Authors:  Marina Majaj; Ludwig T Weckbach
Journal:  Front Cardiovasc Med       Date:  2022-09-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.